Jul 02, 2026
15 MIN READ

Which Is Safer: Mounjaro or Ozempic?

Both Mounjaro and Ozempic are FDA-approved medications for weight management, but they work through different mechanisms. Understanding their safety profiles helps you make an informed choice about which option aligns with your health needs.

GLP-1 weight loss starts at $129/mo Provider-reviewed options. No membership fees.

See if you qualify →

Jul 02, 2026
15 MIN READ

which is safer: mounjaro or ozempic? — PlexusDx GLP-1 education

Last reviewed: July 2, 2026

Last updated: July 2, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.

Mounjaro (tirzepatide) and Ozempic (semaglutide) represent two of the most widely prescribed GLP-1 receptor agonists for weight loss, each backed by rigorous clinical trial data. While both medications have demonstrated strong efficacy and generally favorable safety records, they differ in their mechanism of action, side effect patterns, and suitability for individual patients. PlexusDx offers compounded versions of both medications to help you find the right fit for your body and goals.

How Mounjaro and Ozempic Work Differently in Your Body

Ozempic is a pure GLP-1 receptor agonist, meaning it activates only one hormone pathway in the brain and gut to reduce appetite and slow digestion. Mounjaro takes a dual approach by activating both GLP-1 and GIP receptors—a mechanism called GLP-1/GIP co-agonism—which targets appetite control through two separate biological channels simultaneously. This fundamental difference in how the medications function can influence their safety and effectiveness profiles.

The dual-pathway design of Mounjaro allows many patients to achieve greater weight loss with potentially lower doses compared to single-pathway GLP-1 agents. In the SURMOUNT trials, tirzepatide demonstrated weight reductions of up to 22.5% of body weight, while semaglutide in the STEP trials showed reductions up to 17.4%. Both medications have strong safety data, but the choice between them often depends on individual tolerability and how your genetic makeup influences peptide signaling.

Safety Profile Comparison: Gastrointestinal Side Effects

Both medications most commonly cause nausea, vomiting, diarrhea, and constipation, with gastrointestinal effects occurring in the majority of users during initial titration phases. In clinical trials, Mounjaro users reported gastrointestinal side effects at slightly higher rates than Ozempic users, though most side effects were mild to moderate and decreased over time as the body adapted. The severity and duration of these effects vary widely between individuals and often depend on how quickly the dose is increased and individual metabolic sensitivity.

PlexusDx's Precision Peptide Genetic Test can identify genetic variants in the GLP1R and GIPR pathways that may predict how your body responds to these medications and which gastrointestinal effects you might experience. Patients with certain genetic predispositions may tolerate one medication better than the other, making personalized testing a valuable tool for reducing side effects before committing to treatment.

Rare but Serious Safety Considerations for Both Medications

Both semaglutide and tirzepatide carry black-box warnings regarding medullary thyroid carcinoma risk in animal studies, meaning they should not be used by patients with personal or family history of medullary thyroid cancer or multiple endocrine neoplasia type 2. Additionally, both medications are associated with risk of severe pancreatitis, diabetic retinopathy worsening in patients with existing eye disease, and gallbladder-related complications. These serious risks affect a small percentage of users but require careful patient selection and medical supervision.

Acute kidney injury has been reported in both drug classes, particularly in patients who experience severe dehydration from vomiting or diarrhea. Patients should maintain adequate hydration and alert their provider to persistent gastrointestinal symptoms. Neither medication should be used during pregnancy, as animal studies suggest potential harm to the fetus.

Choosing Between Mounjaro and Ozempic for Your Personalized Plan

The decision between these medications should account for your medical history, family history of thyroid or endocrine disease, existing gastrointestinal conditions, and how your genetics influence GLP-1 and GIP receptor sensitivity. Patients with mild initial nausea on one medication sometimes tolerate the other better due to differences in receptor distribution throughout the digestive tract. Starting with a lower microdose and advancing slowly allows your body to adapt while minimizing side effect severity.

PlexusDx offers compounded Semaglutide Injection starting at $149/mo and compounded Tirzepatide Injection starting at $249/mo through licensed 503A pharmacies, with pricing that stays flat regardless of dose level—your dose may need to go up, but your price won't. For patients wanting to trial both mechanisms, PlexusDx's GLP-Squared Injection combines semaglutide and tirzepatide in one formulation, starting at $249/mo. PlexusDx also provides the Precision Peptide Genetic Test as a $99 add-on after your first month of treatment to map your individual peptide pathways and optimize medication selection.

How Your Genetics Influence GLP-1 Response

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month of treatment) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Tirzepatide Injection starts at $249/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.

Frequently Asked Questions

Is Mounjaro safer than Ozempic or vice versa?

Both medications have strong safety records when prescribed appropriately. Mounjaro may cause slightly more gastrointestinal side effects initially, while Ozempic has been used longer in clinical practice. Neither is inherently safer—the best choice depends on your medical history, genetic factors, and individual tolerability. PlexusDx can help you explore both options with compounded versions starting at $149/mo for semaglutide and $249/mo for tirzepatide.

What clinical trial data supports the safety of these medications?

Ozempic's STEP trials (conducted across multiple years with over 4,000 participants) demonstrated consistent weight loss with a safety profile comparable to placebo for non-serious events. Mounjaro's SURMOUNT trials (three large studies in over 2,500 total participants) showed greater weight loss than semaglutide with gastrointestinal side effects that were generally manageable. Both trials found serious adverse events to be rare and comparable to background population rates.

Does PlexusDx offer both medications, and how do their costs compare?

Yes, PlexusDx offers compounded Semaglutide Injection (starts at $149/mo) and compounded Tirzepatide Injection (starts at $249/mo) through licensed 503A pharmacies. Pricing remains flat across all dose levels—your dose may increase, but your monthly price won't. PlexusDx serves all 50 states without insurance requirements and accepts HSA/FSA payments for added savings.

What side effects should I expect, and how long do they last?

Nausea, vomiting, constipation, and diarrhea are most common during the first 2–4 weeks of treatment or after dose increases; they typically diminish within 1–2 months as your body adjusts. Serious side effects like pancreatitis or acute kidney injury are rare. Slow dose titration and staying hydrated reduce side effect severity. If symptoms persist or worsen, contact your prescribing provider immediately.

How can genetic testing help me choose between these medications?

PlexusDx's Precision Peptide Genetic Test ($99 add-on) examines key genetic variants in GLP1R, GIPR, FTO, and MC4R pathways—mapping 14 pathways, 49 peptides, and 150+ clinical insights. Your genetic profile predicts how strongly you respond to GLP-1 vs. GIP signaling, which side effects you may experience, and whether tirzepatide (dual-pathway) or semaglutide (single-pathway) aligns better with your biology.

Real prescribers. Published prices. No surprises.

Licensed providers in all 50 states. Online intake. No insurance, no membership required.

Start My Intake →

~60 seconds · $0 charged until your provider approves